- Markets
- Chemicals
- ASTEC
ASTEC
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Astec Lifesciences Says Mugdha Amol Khare Named As CFO
July 29 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
ASTEC LIFESCIENCES - MUGDHA AMOL KHARE NAMED AS CFO
Further company coverage: ASTE.NS
(([email protected];))
July 29 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
ASTEC LIFESCIENCES - MUGDHA AMOL KHARE NAMED AS CFO
Further company coverage: ASTE.NS
(([email protected];))
Astec Lifesciences Says Resignation Of K. Suryanarayan From Position Of CFO
May 2 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
ASTEC LIFESCIENCES LTD - RESIGNATION OF K. SURYANARAYAN FROM POSITION OF CFO
INDIA'S ASTEC LIFESCIENCES MAR-QUARTER CONSOL NET LOSS 9.7 MILLION RUPEES VERSUS LOSS 49.8 MILLION RUPEES
ASTEC LIFESCIENCES MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.54 BILLION RUPEES VERSUS 1.27 BILLION RUPEES
Source text for Eikon: ID:nBSE4frWW3
Further company coverage: ASTE.NS
(([email protected];))
May 2 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
ASTEC LIFESCIENCES LTD - RESIGNATION OF K. SURYANARAYAN FROM POSITION OF CFO
INDIA'S ASTEC LIFESCIENCES MAR-QUARTER CONSOL NET LOSS 9.7 MILLION RUPEES VERSUS LOSS 49.8 MILLION RUPEES
ASTEC LIFESCIENCES MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.54 BILLION RUPEES VERSUS 1.27 BILLION RUPEES
Source text for Eikon: ID:nBSE4frWW3
Further company coverage: ASTE.NS
(([email protected];))
REFILE-India's Godrej family agrees to split conglomerate into two
Corrects to "agrees" from "agree" in headline
BENGALURU, May 1 (Reuters) - India's Godrej family has decided to restructure its shareholding in the conglomerate to operate as two entities, Godrej Enterprises and Godrej Industries, according to a filing late on Tuesday.
The realignment will be implemented after the relevant regulatory approvals have been obtained, after which the two companies will continue to use the Godrej brand, it added.
Godrej Enterprises Group (GEG) will be headed by 75-year-old Jamshyd Godrej as chairperson and managing director and his niece Nyrika Holkar as executive director.
GEG operates across aerospace, aviation, defence and liquid engines among others.
Jamshyd Godrej was earlier serving as managing director and chairman of Godrej & Boyce, the privately held company, founded in 1897.
Nadir Godrej, 73, will serve as chairperson of Godrej Industries Group (GIG), which operates via listed companies including Godrej Industries GODI.NS, Godrej Consumer Products GOCP.NS, Godrej Properties GODR.NS, Godrej Agrovet GODE.NS and Astec Lifesciences ASTE.NS. GIG will be controlled by Nadir's brother Adi Godrej and their immediate family.
82-year-old Adi Godrej stepped down as chairman of Godrej Industries in August 2021, handing over the reign to his brother, Nadir Godrej.
Adi Godrej's son Pirojsha Godrej will be named chairperson of GIG, succeeding Nadir Godrej in August 2026.
(Reporting by Ashna Teresa Britto in Bengaluru; Editing by Eileen Soreng)
(([email protected];))
Corrects to "agrees" from "agree" in headline
BENGALURU, May 1 (Reuters) - India's Godrej family has decided to restructure its shareholding in the conglomerate to operate as two entities, Godrej Enterprises and Godrej Industries, according to a filing late on Tuesday.
The realignment will be implemented after the relevant regulatory approvals have been obtained, after which the two companies will continue to use the Godrej brand, it added.
Godrej Enterprises Group (GEG) will be headed by 75-year-old Jamshyd Godrej as chairperson and managing director and his niece Nyrika Holkar as executive director.
GEG operates across aerospace, aviation, defence and liquid engines among others.
Jamshyd Godrej was earlier serving as managing director and chairman of Godrej & Boyce, the privately held company, founded in 1897.
Nadir Godrej, 73, will serve as chairperson of Godrej Industries Group (GIG), which operates via listed companies including Godrej Industries GODI.NS, Godrej Consumer Products GOCP.NS, Godrej Properties GODR.NS, Godrej Agrovet GODE.NS and Astec Lifesciences ASTE.NS. GIG will be controlled by Nadir's brother Adi Godrej and their immediate family.
82-year-old Adi Godrej stepped down as chairman of Godrej Industries in August 2021, handing over the reign to his brother, Nadir Godrej.
Adi Godrej's son Pirojsha Godrej will be named chairperson of GIG, succeeding Nadir Godrej in August 2026.
(Reporting by Ashna Teresa Britto in Bengaluru; Editing by Eileen Soreng)
(([email protected];))
India's Astec LifeSciences drops on weak Q3 results
** Shares of India's Astec LifeSciences ASTE.NS down 4.2% to its lowest levels since Dec 2020
** Agricultural chemicals maker posted Q3 consol net loss of 243.3 mln rupees vs 8.4 mln rupees profit; rev falls by over 50%
** Co on track for fifth consecutive month of decline, longest monthly losing streak since late 2012-early 2013
** About 56,000 shares changed hands by 12:52 p.m. IST, nearly 1.5x 30-day avg
** Stock fell over 17% in Q3 FY2024, and ended CY2023 with a loss of 37.5%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
** Shares of India's Astec LifeSciences ASTE.NS down 4.2% to its lowest levels since Dec 2020
** Agricultural chemicals maker posted Q3 consol net loss of 243.3 mln rupees vs 8.4 mln rupees profit; rev falls by over 50%
** Co on track for fifth consecutive month of decline, longest monthly losing streak since late 2012-early 2013
** About 56,000 shares changed hands by 12:52 p.m. IST, nearly 1.5x 30-day avg
** Stock fell over 17% in Q3 FY2024, and ended CY2023 with a loss of 37.5%
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
Indian agro chemical firms to see two more challenging quarters - Kotak
** Indian fertilizer and agro-chemicals companies will likely face challenges for two more quarters on destocking by customers, Kotak Institutional Equities analysts said
** Add volume growth will remain under pressure until (and including) Q1 calendar year 2024 on a yoy basis due to destocking
** Outlook for the winter-sown crop season is somewhat challenging in India, especially in the south, due to lower water levels - brokerage
** Says recovery after Q1 CY2024 is seen only as modest, and the recent softness in corn prices is a worry in terms of end-demand for CY2024
** Ten out of 20 companies in Kotak's coverage universe, including Best Agrolife BESA.NS, Bharat Rasayan BRSN.NS, Coromandel CORF.NS, India Pesticides IDIP.NS, Meghmani Organics MEGH.NS, Sumitomo SUMH.NS and UPL UPLL.NS posted fall in core earnings and revenue in Q2 vs year ago
** Two cos, Astec LifeSciences ASTE.NS and Sharda Cropchem SHCR.NS, reported losses from yr ago profit
(Reporting by Nallur Sethuraman in Bengaluru)
(([email protected]; (+91 8061822737); Reuters Messaging: [email protected]))
** Indian fertilizer and agro-chemicals companies will likely face challenges for two more quarters on destocking by customers, Kotak Institutional Equities analysts said
** Add volume growth will remain under pressure until (and including) Q1 calendar year 2024 on a yoy basis due to destocking
** Outlook for the winter-sown crop season is somewhat challenging in India, especially in the south, due to lower water levels - brokerage
** Says recovery after Q1 CY2024 is seen only as modest, and the recent softness in corn prices is a worry in terms of end-demand for CY2024
** Ten out of 20 companies in Kotak's coverage universe, including Best Agrolife BESA.NS, Bharat Rasayan BRSN.NS, Coromandel CORF.NS, India Pesticides IDIP.NS, Meghmani Organics MEGH.NS, Sumitomo SUMH.NS and UPL UPLL.NS posted fall in core earnings and revenue in Q2 vs year ago
** Two cos, Astec LifeSciences ASTE.NS and Sharda Cropchem SHCR.NS, reported losses from yr ago profit
(Reporting by Nallur Sethuraman in Bengaluru)
(([email protected]; (+91 8061822737); Reuters Messaging: [email protected]))
India's Astec Lifesciences Posts Sept-Quarter Consol Net Loss
Oct 27 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
INDIA'S ASTEC LIFESCIENCES LTD SEPT-QUARTER CONSOL NET LOSS 134.3 MILLION RUPEES VERSUS PROFIT 183.1 MILLION RUPEES
ASTEC LIFESCIENCES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.11 BILLION RUPEES VERSUS 2 BILLION RUPEES
ASTEC LIFESCIENCES LTD - APPROVAL FOR FURTHER ISSUANCE OF NON-CONVERTIBLE DEBENTURES UPTO AN ADDITIONAL AMOUNT OF 1 BILLION RUPEES
Source text for Eikon: ID:nBSE2rWX3J
Further company coverage: ASTE.NS
(([email protected];))
Oct 27 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
INDIA'S ASTEC LIFESCIENCES LTD SEPT-QUARTER CONSOL NET LOSS 134.3 MILLION RUPEES VERSUS PROFIT 183.1 MILLION RUPEES
ASTEC LIFESCIENCES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.11 BILLION RUPEES VERSUS 2 BILLION RUPEES
ASTEC LIFESCIENCES LTD - APPROVAL FOR FURTHER ISSUANCE OF NON-CONVERTIBLE DEBENTURES UPTO AN ADDITIONAL AMOUNT OF 1 BILLION RUPEES
Source text for Eikon: ID:nBSE2rWX3J
Further company coverage: ASTE.NS
(([email protected];))
India's Astec Lifesciences Posts June-Quarter Consol Net Loss
July 27 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
JUNE-QUARTER CONSOL NET LOSS 81.9 MILLION RUPEES VERSUS PROFIT 114 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.43 BILLION RUPEES VERSUS 1.84 BILLION RUPEES
Source text for Eikon: ID:nNSE3BHCSC
Further company coverage: ASTE.NS
(([email protected];))
July 27 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
JUNE-QUARTER CONSOL NET LOSS 81.9 MILLION RUPEES VERSUS PROFIT 114 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.43 BILLION RUPEES VERSUS 1.84 BILLION RUPEES
Source text for Eikon: ID:nNSE3BHCSC
Further company coverage: ASTE.NS
(([email protected];))
India's Astec LifeSciences falls over 10% after reporting Q4 loss
** Shares of Astec LifeSciences Ltd ASTE.NS fall as much as 10.4% to 1,211.55 rupees, their lowest since March 29
** Agricultural chemicals maker reports consol net loss in March qtr at 49.8 mln rupees ($608,824.28) compared with a profit of 430.5 mln rupees a year earlier
** Co says subdued demand and subsequent correction in prices of key active ingredients led to drop in volumes along with lower realisations, affecting profitability
** Rev from ops fell 53.3% to 1.27 bln rupees
** Co's board appointed K. Suryanarayan as CFO
** Stock trading below its 50-, 100-, and 200-day moving averages
** Moving Average Convergence Divergence (MACD) line falls below the signal line, suggesting bearish bias
** Shares post their sharpest intraday pct loss since March 28
** More than 79,260 shares change hands by 10:05 a.m. IST, 1.3x the 30-day avg
** Stock down 22.8% so far this year, up to last close
($1 = 81.7970 Indian rupees)
(Reporting by Dimpal Gulwani in Bengaluru)
** Shares of Astec LifeSciences Ltd ASTE.NS fall as much as 10.4% to 1,211.55 rupees, their lowest since March 29
** Agricultural chemicals maker reports consol net loss in March qtr at 49.8 mln rupees ($608,824.28) compared with a profit of 430.5 mln rupees a year earlier
** Co says subdued demand and subsequent correction in prices of key active ingredients led to drop in volumes along with lower realisations, affecting profitability
** Rev from ops fell 53.3% to 1.27 bln rupees
** Co's board appointed K. Suryanarayan as CFO
** Stock trading below its 50-, 100-, and 200-day moving averages
** Moving Average Convergence Divergence (MACD) line falls below the signal line, suggesting bearish bias
** Shares post their sharpest intraday pct loss since March 28
** More than 79,260 shares change hands by 10:05 a.m. IST, 1.3x the 30-day avg
** Stock down 22.8% so far this year, up to last close
($1 = 81.7970 Indian rupees)
(Reporting by Dimpal Gulwani in Bengaluru)
India's Astec Lifesciences Posts Mar-Quarter Consol Net Loss
May 2 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
INDIA'S ASTEC LIFESCIENCES LTD MAR-QUARTER CONSOL NET LOSS 49.8 MILLION RUPEES VERSUS PROFIT 430.5 MILLION RUPEES
ASTEC LIFESCIENCES LTD MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.27 BILLION RUPEES VERSUS 2.72 BILLION RUPEES
RECOMMENDED FINAL DIVIDEND OF 1.50 RUPEES PER SHARE
MADHUR GUNDECHA RESIGNS AS CFO
APPOINTS K. SURYANARAYAN AS CFO
Source text for Eikon: ID:nNSE751dxR
Further company coverage: ASTE.NS
(([email protected];))
May 2 (Reuters) - Astec Lifesciences Ltd ASTE.NS:
INDIA'S ASTEC LIFESCIENCES LTD MAR-QUARTER CONSOL NET LOSS 49.8 MILLION RUPEES VERSUS PROFIT 430.5 MILLION RUPEES
ASTEC LIFESCIENCES LTD MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.27 BILLION RUPEES VERSUS 2.72 BILLION RUPEES
RECOMMENDED FINAL DIVIDEND OF 1.50 RUPEES PER SHARE
MADHUR GUNDECHA RESIGNS AS CFO
APPOINTS K. SURYANARAYAN AS CFO
Source text for Eikon: ID:nNSE751dxR
Further company coverage: ASTE.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Astec Lifesciences do?
Astec Lifesciences Limited, established in 1994, is a global leader in manufacturing agrochemicals and pharmaceutical intermediates. The company exports to over 25 countries and holds certifications like Responsible Care from ICCA.
Who are the competitors of Astec Lifesciences?
Astec Lifesciences major competitors are Excel Industries, Punjab Chem. & Corp, India Pesticides, The Yamuna Syndicate, Heranba Industries, Meghmani Organics, Insecticides India. Market Cap of Astec Lifesciences is ₹1,496 Crs. While the median market cap of its peers are ₹1,440 Crs.
Is Astec Lifesciences financially stable compared to its competitors?
Astec Lifesciences seems to be less financially stable compared to its competitors. Altman Z score of Astec Lifesciences is 2.29 and is ranked 7 out of its 8 competitors.
Does Astec Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Astec Lifesciences latest dividend payout ratio is 11.5% and 3yr average dividend payout ratio is 7.39%
How has Astec Lifesciences allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Accounts Receivable
How strong is Astec Lifesciences balance sheet?
Balance sheet of Astec Lifesciences is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Astec Lifesciences improving?
No, profit is decreasing. The profit of Astec Lifesciences is -₹119.6 Crs for TTM, -₹46.93 Crs for Mar 2024 and ₹25.56 Crs for Mar 2023.
Is the debt of Astec Lifesciences increasing or decreasing?
Yes, The debt of Astec Lifesciences is increasing. Latest debt of Astec Lifesciences is ₹498 Crs as of Sep-24. This is greater than Mar-24 when it was ₹489 Crs.
Is Astec Lifesciences stock expensive?
Astec Lifesciences is not expensive. Latest PE of Astec Lifesciences is 0.0, while 3 year average PE is 52.43. Also latest EV/EBITDA of Astec Lifesciences is 0.0 while 3yr average is 28.14.
Has the share price of Astec Lifesciences grown faster than its competition?
Astec Lifesciences has given lower returns compared to its competitors. Astec Lifesciences has grown at ~-25.53% over the last 3yrs while peers have grown at a median rate of -10.69%
Is the promoter bullish about Astec Lifesciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Astec Lifesciences is 66.75% and last quarter promoter holding is 66.75%.
Are mutual funds buying/selling Astec Lifesciences?
The mutual fund holding of Astec Lifesciences is stable. The current mutual fund holding in Astec Lifesciences is 4.0% while previous quarter holding is 4.0%.